Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study

By sjmartinez • November 15, 2023

Rajdev L, Jackie Wang CC, Joshi H, Lensing S, Lee J, Ramos JC, Baiocchi R, Ratner L, Rubinstein PG, Ambinder R, Henry D, Streicher H, Little RF, Chiao E, Dittmer DP, Einstein MH, Cesarman E, Mitsuyasu R, Sparano JA; AIDS Malignancy Consortium. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. Cancer. 2023 Nov 14. doi: 10.1002/cncr.35110. Epub ahead of print. PMID: 37962072.

Tags: CD4 count >100/µL, HIV cancer, immunotherapy, Infectious Diseases, nivolumab, Publications

Antimicrobial use before and during COVID-19: data from 108 Veterans Affairs medical centers

Goetz MB, Willson T, Rubin MA, Stevens VW, Graber CJ. Antimicrobial use before and during COVID-19: data from 108 Veterans Affairs medical centers. Antimicrob Steward[...]

Rapid and comprehensive detection of viral antibodies and nucleic acids via an acoustofluidic integrated molecular diagnostics chip: AIMDx

Qian J, Xia J, Chiang S, Liu JF, Li K, Li F, Wei F, Aziz M, Kim Y, Go V, Morizio J, Zhong R, He[...]

Mpox primer for clinicians: what makes the difference in 2024?

Abdel-Rahman SM, Bayıcı BZ, Keske Ş, Kuşkucu M, Özsürekçi Y, Rimoin AW, Rodriguez-Morales AJ, Ergönül Ö. Mpox primer for clinicians: what makes the difference in[...]